The primary objective of this study is to compare the efficacy of ONO-2506 versus placebo in neurological stroke outcome in patients with acute ischemic stroke.
- ONO-2506 (Proglia)Drug
- Allocation: Randomized
- Masking: Double-Blind
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Patients will be ranomized to receive either ONO-2506 (4 mg/kg/hr or 10 mg/kg/hr) in 5 consecutive daily 1hour infusion doses or placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Modified Rankin Scale score at 90 days after stroke onset.|
|Primary||Modified Rankin Scale|